This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp



PROTECTING, MAINTAINING AND IMPROVING THE HEALTH OF ALL MINNESOTANS

January 2, 2019

Senator Michelle Benson Chair, Health & Human Services Policy & Finance Minnesota Senate Building, Room 3109 95 University Avenue W. St. Paul, MN 55155

Senator Warren Limmer Chair, Judiciary & Public Safety Policy & Finance Minnesota Senate Building, Room 3221 95 University Avenue W. St. Paul, MN 55155 Representative Tina Liebling Chair, Health & Human Services Finance State Office Building, Room 477 100 Rev. Dr. Martin Luther King Jr. Blvd. St. Paul, MN 55155

Representative Rena Moran Chair, Health & Human Services Policy State Office Building, Room 575 100 Rev. Dr. Martin Luther King Jr. Blvd St. Paul, MN 55155

Representative Carlos Mariani Chair, Public Safety & Criminal Justice Reform Finance & Policy State Office Building, Room 381 100 Rev. Dr. Martin Luther King Jr. Blvd St. Paul, MN 55155

Dear Honorable Chairs:

In accordance with Minnesota Statutes, section 152.27, subdivision 2, paragraph (b), I am providing formal notice of my decision to add Alzheimer's disease as a new qualifying condition for Minnesota's medical cannabis program. Under state law, the new condition will take effect in August 2019.

This year, as in years past, the Minnesota Department of Health used a formal petitioning process to solicit public input on potential qualifying conditions. Throughout June and July, Minnesotans were invited to submit petitions to add qualifying conditions. The process included <u>public comments</u>, a <u>citizens' review panel</u> and a set of research summaries for each condition prepared by Minnesota Department of Health staff.

Petitioners put forward seven conditions this year: Alzheimer's disease, hepatitis C, juvenile idiopathic arthritis, opioid use disorder, panic disorder, psoriasis and traumatic brain injury. After reviewing the research summaries and other input, I decided to approve the addition of Alzheimer's disease.

Alzheimer's disease is a neurodegenerative disorder that mainly affects elderly people. It is the most common cause of dementia. Other symptoms include cognitive impairment, delusion, depression and agitation. The MDH research brief cited two available studies, which found that after cannabis use some patients saw improvements in disruptive nighttime behaviors and agitation.

Under current state rules, patients certified to have Alzheimer's disease will become eligible to enroll in the program on July 1, 2019, and receive medical cannabis from the state's two medical cannabis manufacturers beginning Aug. 1, 2019. As with the program's other qualifying conditions, patients will need advance certification from a Minnesota health care provider. More details on the process are available on the Medical Cannabis website.

I would be happy to discuss this addition with you and answer any questions you may have.

Sincerely,

Jan K. Malcolm

Commissioner P.O. Box 64975

St. Paul, MN 55164-0975